Antibody formats
Innate Pharma designs therapeutic antibodies to stimulate immune cells, aiming for sustained tumor control through a multicellular response.

A clinical-stage biotechnology company, Innate Pharma develops immunotherapies for cancer patients.
innate-pharma.comCrawled Nov 9, 2026
Innate Pharma designs therapeutic antibodies to stimulate immune cells, aiming for sustained tumor control through a multicellular response.
IPH4502 is a novel topoisomerase I inhibitor Antibody Drug Conjugate (ADC) conjugated to exatecan targeting Nectin-4.
Lacutamab (IPH4102) is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is currently in clinical trials for treatment of cutaneous T-cell lymphoma (CTCL), an orphan disease, and peripheral T cell lymphoma (PTCL).
Monalizumab (IPH2201) is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor infiltrating cytotoxic CD8+ T cells and NK cells.
The company develops antibody-based therapies that use the immune system to treat cancer and other life-threatening diseases.
Immunotherapy has been a revolution in cancer treatment. The objective is to induce the immune system to recognize and eliminate tumor cells. Innate Pharma has specialized in immunotherapy since its inception in 1999.
Innate Pharma researches innate immunity and NK cells, with publications in high-impact journals since 1999.
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its financial update for the nine months ended September 30, 2026.
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its executive team will participate in the following investor conferences:
AstraZeneca delayed the PACIFIC-9 Phase 3 trial data readout to the first half of 2027, citing the study’s event-driven nature.
Innate Pharma specializes in discovering and developing drugs targeting the immune system for patients with unmet medical needs.
The company applies expertise in innate immunity and antibody engineering to create cancer treatments.
Innate Pharma enters strategic partnership with Sobi to License lacutamab in T-cell lymphoma
Media and Investor Relations contact details Stéphanie Cornen communication@innate-pharma.com
Innate Pharma SA releases its financial performance for the first nine months of 2026, covering the period ending September 30. The biopharmaceutical company provides an update on its business operations and key financial metrics during this period.
Innate Pharma delays its PACIFIC-9 Phase 3 trial readout to the first half of 2027, shifting from the previously announced second half of 2026. AstraZeneca, the study partner, adjusts the timeline due to the trial’s event-driven design. The update reflects the need to await key clinical milestones before releasing high-level data.
Innate Pharma’s executive team presents at the **Stifel Healthcare Conference** and **Jefferies Global Healthcare Conference**. The clinical-stage biotech company focuses on developing immunotherapies for cancer patients. These events provide a platform for discussing its pipeline and strategic direction with investors.
Innate Pharma releases its consolidated financial performance for the first half of 2026, covering the period ending June 30. The company provides a business update alongside its financial results, with full statements available in the attached press release.
Innate Pharma and Sobi finalize their strategic partnership after meeting antitrust and other regulatory requirements. The collaboration follows months of negotiations and regulatory review. Both companies specialize in biopharmaceuticals, with Innate focusing on immuno-oncology and Sobi in rare disease therapies.
Innate Pharma raises €30 million through an offering of ordinary shares. The company specializes in immuno-oncology therapies and leverages its proprietary Innate Immune Receptors (IIR) platform. This funding supports research and development in cancer treatments.